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Abstract
Hypofunction of N-methyl-D-aspartate receptors (NMDARs) in inhibitory GABAergic interneurons is implicated in
the pathophysiology of schizophrenia (SZ), a heritable disorder with many susceptibility genes. However, it is still
unclear how SZ risk genes interfere with NMDAR-mediated synaptic transmission in diverse inhibitory interneuron
populations. One putative risk gene is neuregulin 1 (NRG1), which signals via the receptor tyrosine kinase ErbB4,
itself a schizophrenia risk gene. The type I isoform of NRG1 shows increased expression in the brain of SZ
patients, and ErbB4 is enriched in GABAergic interneurons expressing parvalbumin (PV) or cholecystokinin (CCK).
Here, we investigated ErbB4 expression and synaptic transmission in interneuronal populations of the hippocam-
pus of transgenic mice overexpressing NRG1 type I (NRG1tg-type-I mice). Immunohistochemical analyses con-
firmed that ErbB4 was coexpressed with either PV or CCK in hippocampal interneurons, but we observed a
reduced number of ErbB4-immunopositive interneurons in the NRG1tg-type-I mice. NMDAR-mediated currents in
interneurons expressing PV (including PV basket cells) or CCK were reduced in NRG1tg-type-I mice compared to
their littermate controls. We found no difference in AMPA receptor–mediated currents. Optogenetic activation (5
pulses at 20 Hz) of local glutamatergic fibers revealed a decreased NMDAR-mediated contribution to disynaptic
GABAergic inhibition of pyramidal cells in the NRG1tg-type-I mice. GABAergic synaptic transmission from either
PV or CCK interneurons, and glutamatergic transmission onto pyramidal cells, did not significantly differ
between genotypes. The results indicate that synaptic NMDAR-mediated signaling in hippocampal interneurons
Significance Statement
Hypofunction of NMDA receptors in inhibitory GABAergic interneurons is implicated in pathophysiology of
schizophrenia (SZ), but it is largely unknown how SZ risk genes interfere with NMDAR-mediated signaling
in specific interneurons. We investigated synaptic transmission in hippocampus of mice overexpressing the
type I isoform of the putative SZ risk gene, NRG1, and found markedly reduced NMDAR-mediated synaptic
responses in GABAergic interneuron types labeled for PV or CCK, which are known to express the NRG1
receptor ErbB4. The NMDAR hypofunction changed synaptic excitatory drive of interneurons during
hippocampal network activity. The observed reductions of NMDAR-mediated transmission in these in-
terneurons may contribute to the hippocampal dysfunction observed with increased NGR1 type I expres-
sion and may provide a link to the genetic predisposition to SZ.
New Research
March/April 2018, 5(2) e0418-17.2018 1–18
is sensitive to chronically elevated NGR1 type I levels. This may contribute to the pathophysiological conse-
quences of increased NRG1 expression in SZ.
Key words: Axo-axonic cell; basket cell; cholecystokinin; ErbB4 receptor; NMDA receptors; parvalbumin;
schizophrenia
Introduction
Many schizophrenia (SZ) susceptibility genes have
been linked to N-methyl-D-aspartate receptor (NMDAR)
signaling (Harrison and Weinberger, 2005; Hall et al.,
2015), consistent with the hypothesis that NMDAR hypo-
function contributes to the disease pathophysiology (Ol-
ney and Farber, 1995; Coyle, 2012; Gonzalez-Burgos and
Lewis, 2012). It has been proposed that NMDAR function
could particularly be impaired in hippocampal and neo-
cortical GABAergic interneurons in the disorder, compro-
mising recurrent inhibition (Carlén et al., 2012; Curley and
Lewis, 2012; Gilmour et al., 2012). Two prominent
GABAergic inhibitory interneuron subpopulations, defined
by mutually exclusive markers parvalbumin (PV) or chole-
cystokinin (CCK), are strongly involved through recurrent
inhibition in rhythmic network activities in the neocortex
and hippocampus (Cobb et al., 1995; Ellender and Paulsen,
2010; Manseau et al., 2010; Lasztóczi et al., 2011; Buzsáki
and Wang, 2012; Fasano et al., 2017; Pelkey et al., 2017).
Disrupted function of either of these interneuron popula-
tions in animal models results in alterations of coordinated
neuronal network activities, particularly the synchronous
gamma frequency (20–80 Hz) oscillations, and causes
behavioral changes associated with the disorder (Belforte
et al., 2010; Nakazawa et al., 2012; Brown et al., 2014;
Schmidt et al., 2014; Cho et al., 2015; Gonzalez-Burgos
et al., 2015; Schmidt and Mirnics, 2015; Huang et al.,
2016; Del Pino et al., 2017; Medrihan et al., 2017; Vargish
et al., 2017). However, whether and how specific SZ sus-
ceptibility genes interfere with NMDAR-mediated synaptic
signaling in these interneurons is still not well known
(Gonzalez-Burgos and Lewis, 2012; Vullhorst et al., 2015).
In this respect, the gene for neuregulin 1 (NRG1) is a
relevant candidate to study because diverse evidence
links it to NMDAR function and SZ pathogenesis (Stefans-
son et al., 2002; Corfas et al., 2004; Gu et al., 2005; Hahn
et al., 2006; Law et al., 2006; Bjarnadottir et al., 2007;
Chong et al., 2008; Pitcher et al., 2011; Weickert et al.,
2013). Moreover, the main receptor for NRG1 signaling,
ErbB4, itself a schizophrenia risk gene (Schizophrenia Work-
ing Group of the Psychiatric Genomics Consortium, 2014), is
expressed in PV and CCK GABAergic interneurons but
not in glutamatergic pyramidal cells (Vullhorst et al., 2009;
Fazzari et al., 2010; Neddens et al., 2011; Del Pino et al.,
2017).
NRG1 has several functionally distinct isoforms, of which
type I (among others) has been reported to be overex-
pressed in SZ (Hashimoto et al., 2004; Law et al., 2006).
Overexpression of NRG1 type I mRNA, or administration of
the protein in early postnatal development, results in
pathophysiological changes reminiscent of schizophrenia
endophenotype in animal models: alterations in rhythmic
gamma-frequency network oscillations (Deakin et al.,
2012) and synaptic plasticity (Agarwal et al., 2014), and a
behavioral phenotype including age-emergent impair-
ment of hippocampal working memory (Chen et al., 2008;
Deakin et al., 2009; Kato et al., 2011; Yin et al., 2013; Luo
et al., 2014). These findings together suggest that NRG1-
ErbB4 signaling may regulate glutamatergic NMDAR-
mediated transmission in interneurons, and that
alterations in this mechanism might contribute to the
pathophysiology of SZ. To investigate this possibility, we
have studied synaptic function in hippocampal interneu-
rons expressing PV or CCK in mice overexpressing NRG1
type 1, using a combination of electrophysiological, op-
togenetic, and immunohistochemical techniques.
Materials and Methods
Ethics statement
All animal procedures were performed in accordance
with British Home Office regulations and personal and
project licenses held by the authors, following local ethics
review at the University of Oxford (UK).
Experimental animals
Experiments were conducted on heterozygous (at least
1 month old) NRG1 type I transgenic (NRG1tg-type-I) mice
of either sex, overexpressing NRG1 type I (1a-isoform)
under a Thy-1.2 promoter (RRID:MGI:3530784; Michailov
et al., 2004). To specifically express fluorescent marker in
PV interneurons, PV-Cre/ mice (The Jackson Labora-
tory, B6;129P2-Pvalbtm1[cre]Arbr/J; RRID:IMSR_JAX:
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017320) were crossbred with Ai9/ mice (The Jackson
Laboratory, B6.Cg-Gt[ROSA]26Sortm9[CAG-tdTomato]
Hze/J; RRID:IMSR_JAX:007909) to produce tdTomato ex-
pression in the PV cells (Figs. 1, 2 and 3). The female
offspring were further crossed with the NRG1tg-type-I /
males. For the experiments in Fig. 4, Lhx6-eGFP/ fe-
males expressing GFP in PV cells (The Jackson Laboratory,
Tg[Lhx6-EGFP]BP221Gsat/M, RRID:MMRRC_000246-MU)
were crossbred with male NRG1tg-type-I / mice, and an-
atomically identified basket cells in hippocampal slices
(Nissen et al., 2010) were defined as PV basket cells
(PVBCs) and confirmed immunonegative for axonal can-
nabinoid receptor type 1 (CB1R; Armstrong and Soltesz,
2012). To express fluorescent marker in CCK neurons,
BAC-CCK-Cre/ mice (Geibel et al., 2014; RRID:MGI:
5575864) were crossed with the Ai9/mice for tdTomato
expression in the CCK cells. For the virus transduction
studies, PV-Cre/ females (The Jackson Laboratory, B6;
129P2-Pvalbtm1[cre]Arbr/J; RRID:IMSR_JAX:017320),
heterozygous BAC-CCK- Cre / females (RRID:MGI:
5575864), or CaMKII-Cre/ females (B6.Cg-Tg[Camk2a-
cre]T29-1Stl/J; RRID:IMSR_JAX:005359) were crossbred
with male NRG1tg-type-I / mice. The Cre-expressing
NRG1tg-type-I and control littermates were injected with
adeno-associated virus construct encoding opsin.
Opsin construct transduction
Mice were anesthetized with 2%–4% isoflurane (CHEBI:
6015). AAV2-ChR2-eYFP (in some cases AAV5-ChR2-
eYFP) was stereotactically injected via 33-gauge needle
attached to a Microlitre Syringe (Hamilton) into midventral
CA3 or dorsal CA1 hippocampus. The vector sequence
was: pAAV-EF1a-sCreDIO hChR2(H134R)-EYFP-WPRE
(Vector Core Services, Gene Therapy Center Virus, Uni-
versity of North Carolina). In each hemisphere, a craniot-
omy was performed using a micro-torque, and a total
volume of 800 nl virus suspension (viral particle suspen-
sion titer 4  1012/mL) was delivered at 80 nl/min by a
Micro Syringe Pump Controller (World Precision Instru-
ments). The scalp incision was sutured, and mice were
allowed to recover for 10–21 d. Light exposure of brain
tissue during preparation of slices was minimized to avoid
photoactivation of ChR2. In experiments, ChR2 was acti-
vated by a fixed-spot laser (Laser nominal maximum power
100 mW; Rapp OptoElectronics) light (20-m diameter to
evoke IPSCs with minimal stimulation of GABAergic fibers,
and 80-m diameter in experiments stimulating glutamater-
gic fibers with 20-Hz train stimulation) via the microscope
objective.
Identification of interneuron populations and
pyramidal cells
CCK interneurons in Fig. 1 were tagged by the fluores-
cent marker tdTomato using the crossed mouse line:
BAC-CCK-Cre tg with Ai9 mice. In Fig. 2, CCK-expressing
interneurons were identified with positive immunoreaction
for somatic pro-CCK or by positive immunoreaction for
axonal CB1R when the soma recovery was compromised.
In Figs. 1, 2, and 3, the PV-expressing cells were identified
by genetic fluorescence marker in PV-Cre mice crossed
with Ai9 mice. Recorded cells were filled with neurobiotin
(0.3% w/v) and visualized, and some were anatomically
identified as basket cells by their characteristic predomi-
nant axon distribution in str. pyramidale and the lack of
axo-axonic cell axon terminal cartridges (Klausberger and
Somogyi, 2008). In addition, the basket cells in Fig. 4 were
confirmed immunonegative for axonal CB1R (Katona et al.,
1999; Tsou et al., 1999; Bodor et al., 2005; Armstrong and
Soltesz, 2012). Pyramidal cells (PCs) were identified by their
somatodendritic structure with mushroom spines along the
dendrites.
Electrophysiological recordings
Mice were anesthetized with sodium-pentobarbitone
and decapitated. After brain removal, horizontal (for mid-
ventral hippocampus) or coronal (for dorsal hippocampus)
brain slices (250 m) were cut using a vibrating microtome
(Microm HM650V) in oxygenated (95% O2/5% CO2) ice-
cold (0–4°C) cutting solution. The composition of the
cutting solution was (in mM): 75 sucrose, 87 NaCl, 2.5 KCl,
0.5 CaCl2, 7 MgCl2, 1.0 NaH2PO4, 25 NaHCO3, 25 glu-
cose, pH 7.4, bubbled with 95% O2/5% CO2. Slices were
kept submerged at 32°C in the sucrose solution for 20–25
min before being transferred to an interface chamber in
which they were maintained in Earle’s balanced salt so-
lution (Thermo Fisher Scientific, 14155063) with 3 mm
Mg2 and 1 mm Ca2 at room temperature (20–24°C) for
at least 60 min before starting experiments. In the experi-
ments, the slices were superfused with oxygenated record-
ing solution at 5 mL/min in a submerged-type recording
chamber at 30°C (Luigs & Neumann) mounted on Olympus
BX51 microscope stage (20 objective, 2–4 zoom) with
epifluorescence and filters (eGFP, eYFP, tdTomato) and
DIC-IR with a CCD camera (Till Photonics). The superfusion
solution was (in mM): 119 NaCl, 2.5 KCl, 2.5 CaCl2, 1.3
MgSO4, 1.25 NaH2PO4, 25 NaHCO3, and 11 glucose, final
pH 7.4 (equilibrated with 95% O2/5% CO2).
Borosilicate-glass microelectrodes were pulled (P-97,
Sutter Instrument) from GC150F-10 capillaries (Harvard
Apparatus). Pipettes (6–8 M) were filled (Figs. 2, 3, and
4) with (in mM): 145 Cs-methanesulfonate, 20 HEPES, 10
CsOH, 8 NaCl, 0.2 CsOH-EGTA, 2 ATP-Mg, 0.3 GTP-Na,
5 QX-314, and 0.2%–0.5% neurobiotin (295mOsm, pH 7.2).
In Figs. 5 and 6, 145 K-gluconate or K-methanesulfonate (with
10 KOH, and 0.2 K-EGTA) were used instead. Recordings
with 30% change in access resistance were excluded.
Liquid-junction potential was not corrected. Data were
recorded with a Multiclamp 700B amplifier, low-pass fil-
tered (cutoff frequency 2 kHz), digitized (10 kHz, Digi-
data 1400), acquired by Clampex, and analyzed by
pClamp10.2 (Molecular Devices, SCR_011323).
Extracellular electrical stimuli were applied via a bipolar
electrode (50–100 s, 50–400 A) in stratum oriens and
current isolator (CBAPC75PL1, FHC) every 15 s. Synaptic
currents were post hoc lowpass filtered at 1 KHz. Phar-
macologically isolated AMPA receptor (AMPAR)-mediated
EPSC peak amplitude was recorded at –60 mV, and the
NMDAR-mediated EPSC amplitude was measured in the
presence of the AMPA/kainate receptor blocker NBQX at
a membrane potential 40 mV positive to their measured
reversal potential estimated by a linear fitting curve of the
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Figure 1. ErbB4 expression in PV and PV– interneurons and the ErbB4 expression levels in hippocampus of WT and the NRG1tg-type-I
mice. A, Immunostaining for ErbB4, the NRG1 receptor, in the ventral hippocampus CA3 area neurons using highly specific rabbit
anti-ErbB4 (polyclonal anti-antiserum 5941; Neddens and Buonanno, 2010). A1, Double immunolabeling for PV (Cy3) and ErbB4
(Alexa488). Merged image shows double-labeled neurons (arrowhead) and ErbB4 interneurons immunonegative for PV (arrows). s.r,
stratum radiatum. A2, In mice with genetic fluorescence marker (tdTomato) in CCK cells (tdTom-CCK), ErbB4 immunostaining with
Alexa Fluor 488 shows the expression in many CCK neurons in s.r. and stratum pyramidale (s.p.). Cre-dependent tdTomato signal
is strong in putative CA3 interneurons (soma in s.r.) and weaker in s.p., where the majority of pyramidal cell somata are located
(contrast adjustment in the image). In merged image, arrowheads point at interneuron somata with both fluorescent signals. Scale
bars, 50 m. Confocal microscope images. B–D, Cell density analysis of hippocampal interneurons immunopositive for ErbB4 in the
WT and NRG1 type I–overexpressing mice (NRG1tg-type-I mice). B1, ErbB4 immunoreaction (20-m stack image) in sample
hippocampal sections of WT (left) and NRG1tg-type-I mice (right). Scale bar, 100 m. B2, Box plots show ErbB4 cell soma density
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current–voltage relation for at least 20 evoked NMDAR
EPSCs measured between –20 and 65 mV (Deleuze and
Huguenard, 2016). In cells where no NMDAR EPSC was
detected, the current was defined as 0.mEPSC record-
ings (2 min for AMPAR and 2 min for NMDAR mEPSCs)
were acquired at 20 kHz and bandpass filtered offline
(cutoff frequencies 4 Hz to 5 or 6 kHz at –65 mV, 2–500 Hz
at 40 mV) for analysis. Events were detected with an
amplitude threshold-crossing algorithm in pClamp (Mo-
lecular Devices, SCR_011323). Criteria for threshold de-
tection for NMDAR mEPSCs (at 40 mV) were amplitude
threshold 7 pA, duration 0.8–200ms, with noise rejection 0.8
ms. For the AMPAR mEPSCs (at –65 mV) the amplitude
threshold was 5 pA, duration 0.5–100 ms, with noise
rejection 0.5 ms) evaluated after blockade of AMPARs
with NBQX (25 M). The same detection criteria were
employed for all cells. Number of AMPAR mEPSCs inves-
tigated in the analyses were as follows: in wild-type (WT)
basket cells (median and interquartile range), 424 and
279–680 events (7 cells); in NRG1tg-type-I basket cells, 394
and 301–470 events (6 cells); in WT pyramidal cells, 134
and 128–205 events (7 cells); in NRG1tg-type-I pyramidal
cells, 95 and 64–150 events (10 cells). The numbers of
NMDAR mEPSCs measured in similar time window were
as follows: in WT basket cells (median and interquartile
range), 513 and 178–792 events (6 cells); in NRG1tg-type-I
basket cells, 348 and 280–520 events (6 cells). mEPSC
frequency was calculated from the 2-min time window as
the event occurrence in Hz. Average mEPSC amplitude
was calculated in each cell from all events occurring in the
2-min time window.
In experiments using optogenetic stimulation of GABAergic
fibers, the monosynaptic IPSCs were measured at 0 to –10
mV. Optogenetic stimulation of the glutamatergic fibers (5
pulses at 20 Hz) was applied every 30 s while the disyn-
aptic IPSCs were recorded (on average at 11 mV; see
Results) in postsynaptic pyramidal cells. The optogeneti-
cally evoked postsynaptic currents were lowpass filtered
offline at 1 kHz, and the evoked postsynaptic current charge
was analyzed with pClamp10.2 (Molecular Devices,
SCR_011323).
Drugs
Drugs were purchased as follows: 2,3-dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt
(NBQX) from Abcam; DL-2-amino-5-phosphonopentanoic acid
sodium salt (DL-AP5), picrotoxin (PiTX), CGP55845, 4-[(2S)-
2-[(5-isoquinolinylsulfonyl)
methylamino]-3-oxo-3-(4-phenyl-1-piperazinyl)propyl]
phenyl isoquinolinesulfonic acid ester (KN-62), and (RS)--
methyl-4-carboxyphenylglycine (MCPG) from Tocris Biosci-
ence. Stocks were diluted (1:1000) in ddH2O, DMSO, or
ethanol.
Statistics
A t test was used for data that were normally distributed
(Shapiro–Wilk test) and with n  10 in tested groups.
Otherwise, a Mann–Whitney U test or rank sum test was
used.
Anatomic and immunohistochemical processes
After whole-cell recordings, slices were fixed overnight
at 4°C in 4% paraformaldehyde (NIFCHEM:birnlex
3072_2), 0.05% glutaraldehyde (NIFINV:birnlex 3070_2),
and 0.2% picric acid in 0.1 M sodium phosphate buffer
(PB), then washed in 0.1 M PB. Slices were embedded in
20% gelatin and sectioned (40–60 m) with a microtome
(Leica VT1000) in 0.1 M PB, then washed in 50 mM Tris-
buffered saline (TBS, pH 7.4) with 0.3% Triton X-100
(TBS-Tx) and incubated with streptavidin-Alexa Fluor 488
(1:2000, Invitrogen, S-32354) or -Cy3 (1:2000, Thermo
Fisher, S-A1010), and finally washed in 50 mM TBS-Tx.
Sections mounted in Vectashield (Vector Laboratories)
were examined with an epifluorescence microscope
(DM5000-B, Leica Microsystems) using appropriate filter
sets and a CCD camera (ORCA-ER, Hamamatsu).
Sections for immunoreactions were washed in 50 mM
TBS-Tx, blocked in 20% normal horse serum (NHS, Vec-
tor Laboratories) in TBS-Tx for at least 1 h at room tem-
perature (20–24°C), and incubated in primary antibodies
for 48 h at 4°C in TBS-Tx with 1% NHS. Fluorochrome-
conjugated secondary antibodies were applied overnight
at 4°C in TBS-Tx with 1% NHS. Mounted sections in
continued
(measured up to 20-m depth from the section surface) in WT (blue, n  9 sections in 3 mice) and NRG1tg-type-I (red, 12 sections in
3 mice) mice hippocampi. The plot shows median and interquartile range. Fewer ErbB4 somata were detected in the NRG1tg-type-I
mice compared to the WT mice in all hippocampal areas. From the left: whole hippocampus including areas CA1, CA2, and CA3; area
CA1–2 restricted to alveus, stratum oriens, and stratum pyramidale; area CA1–2 restricted to stratum radiatum and lacunosum-
moleculare; area CA3 containing alveus with strata oriens and pyramidale; and area CA3 with strata lucidum and radiatum and
lacunosum-moleculare. p-values compare data between genotypes (Mann–Whitney U test). C1, Immunoreaction for PV in the same
sections as in B1. C2, Cell density analyses show no difference in the observed PV cell somata between the two genotypes as
indicated by p values (Mann–Whitney U test). Box plots as in B2. D1, Merged ErbB4 and PV immunolabeling in the sample sections
above. D2, Box plots show proportion of the double-labeled cells (co-immunoreactive for ErbB4 and PV) in the PV cell population
in WT and NRG1tg-type-I mice. The analyses show unaltered proportion in the whole hippocampus and in most subregions compared
separately. The significant p value is bolded. E, Immunoblot analysis of ErbB4 expression levels in WT and NRG1tg-type-I mice using
hippocampal extracts. E1, The antibody against ErbB4 detects a band of the predicted protein size (150 kDa) in hippocampal
protein extracts. Left lane, no nonspecific bands were detected in the secondary-only antibody control (right lane). E2, Hippocampal
extracts from 6 WT and 6 NRG1tg-type-I mice of both genders (3 males and 3 females in each genotype in scrambled order) tested for
ErbB4 expression. GAPDH was used as a loading control. E3, Box plot shows (mean and interquartile range) densitometry analysis
comparison of the ErbB4 levels normalized by the GAPDH in the 12 hippocampal extracts (6 in both genotypes including 3 males and
3 females). The results indicate a general trend to lower ErbB4 levels in NRG1tg-type-I mice, but with no significant difference between
the genotypes (Mann–Whitney U test).
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Figure 2. Reduced synaptic NMDAR-mediated currents in hippocampal interneurons expressing PV or CCK in the NRG1tg-type-I mice.
A, Interneurons expressing PV or CCK in the CA3 area. A1, Sample image of a recorded PV interneuron identified by PV
expression-dependent fluorescent genetic marker tdTomato (tdTom-PV). Recorded cells were also visualized with filled neurobiotin
(nb, Alexa Fluor 488). A2, Recorded cells not showing tdTomato signal were identified as CCK interneurons post hoc with positive
somatic immunoreaction for pro-CCK (left; Cy5, arrowhead) or in the absence of recovered soma and dendrites (right) by positive
reaction for axonal cannabinoid receptor type 1 (CB1R, Cy3). Scale bars from left: 10, 20, and 10 m, respectively. B, Reduced
NMDAR- versus AMPAR-mediated EPSCs ratio (N/A ratio) in glutamatergic synaptic input to interneurons expressing PV. Electrical
stimulation was applied in CA3 stratum oriens aiming to activate associative/commissural pathways. AMPAR-mediated EPSCs were
recorded at –60 mV (in PiTX, 100 M) and blocked by NBQX (25 M) to record NMDAR-mediated EPSCs (at 40 mV from their reversal
potential). B1, Averaged EPSCs (10 traces) in sample PV interneurons in WT and NRG1tg-type-I mouse (black, AMPAR EPSCs; green,
NMDAR EPSCs in the presence of NBQX; gray, following application of NMDAR blocker DL-AP5). Scale bars, 100 pA, 25 ms.
B2, Cumulative histograms of the N/A amplitude ratios in all studied PV interneurons (WT, blue line; NRG1tg-type-I, red line). p
indicates difference between the genotypes (Mann–Whitney U test). C, Reduced N/A ratio in glutamatergic synaptic input to the CCK
interneurons. C1, Averaged EPSCs (10) in sample cells in the WT and in the NRG1tg-type-I mouse with scaling as above.
C2, Cumulative histogram quantifying the N/A ratios in CCK interneurons with p indicating significant difference between the
genotypes (Mann–Whitney U test). D, The N/A ratio is unaltered between the genotypes in the CA3 pyramidal cells. D1, Averaged
EPSCs (10 traces) in sample pyramidal cells with scaling as above. D2, Cumulative histograms of the N/A ratios.
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Vectashield were evaluated at 40 magnification using
confocal laser-scanning microscopy (LSM710, Carl Zeiss)
with Zen2008 software. Digital micrographs were con-
structed from z-stacks with ImageJ software (SCR:003070).
Micrographs were only adjusted for brightness and con-
trast. The primary antibodies used were rabbit anti-ErbB4
(polyclonal anti-antiserum 5941, 1:500; Vullhorst et al.,
2009), guinea pig anti-PV (Synaptic Systems, 195004,
RRID:AB_2156476, 1:2000), rabbit anti-proCCK (RRID:
AB_2571674, 1:500; Morino et al., 1994), guinea pig anti-
CB1R (Frontier Science, CB1-GP-af530-1, RRID:
AB_2571593, 1:1000). The secondary antibodies were
CY5 donkey anti–guinea pig (1:250, Jackson ImmunoRe-
search, 706-175-148), CY3 donkey anti–guinea pig (1:
400, Jackson ImmunoResearch, 706-165-148), Alexa
Fluor 647 donkey anti–guinea pig (1:250, Invitrogen, 706-
605-148), Alexa Fluor 488 donkey anti-rabbit (1:500, In-
vitrogen, A21206), Dylight 649 donkey anti-rabbit (1:250,
Jackson ImmunoResearch, 711-495-152).
Cell density analyses
Mice were anesthetized with 2%–4% isoflurane (CHEBI:
6015) at a rate of 1.0–1.5 ml/min and then further anesthe-
tizedwith an intraperitoneal injectionof pentobarbitone sodium
(20% w/v, dosage 0.2 mg/g; Pharmasol). Animals were
perfused with 0.1 M PBS solution (pH 7.4, at 22–24°C)
followed by ice-cold fixative solution; 4% w/v paraformal-
dehyde (NIFCHEM:birnlex 3072_2) with 15% v/v satu-
rated picric acid solution in 0.1 M PB. A vibratome
(VT1000S Leica Microsystems) was used for cutting cor-
onal brain sections (60-m thickness). Sections contain-
ing the hippocampal formation were washed (3–5 times,
10 min) with TBS-Tx and blocked with 20% NHS in
TBS-Tx for 1 h at room temperature (20–24°C). This was
followed by a 2-night incubation with the primary antibod-
ies: rabbit anti-ErbB4 (polyclonal anti-antiserum 5941,
1:500) and guinea pig anti-PV (Synaptic Systems, 195004,
RRID:AB2156476, 1:2000) in TBS-Tx with 1% NHS at 4°C.
After washes (3–5 times, 10 min each) with TBS-Tx, sec-
Figure 3. Reduced synaptic NMDAR-mediated currents in identified PV basket cells in the NRG1tg-type-I mice. Identified PV basket
cells (PVBCs) in the recorded interneuron population (see Fig. 2) show reduced N/A ratio in the NRG1tg-type-I mice. A, Illustration of
a sample PVBC (70-m-thick section) in WT (axon, blue; soma and dendrites, red; s.r., stratum radiatum; s.luc., lucidum; s.p.,
pyramidale; s.o., oriens). Scale, 100 m. B, The N/A EPSC amplitude ratio in identified basket cells. B1, Averaged (10) EPSCs in a
PVBC from WT and NRG1tg-type-I mouse. Black, AMPAR EPSCs at –60 mV; green, EPSCs (at 40 mV from their reversal potential in
the presence of NBQX, 25 M); gray, EPSCs following the application of DL-AP5 (100 M). PiTX (100 M) was present in all
experiments. Scale bars, 50 pA, 25 ms. B2, Plot shows N/A ratio of every identified PVBC in WT (blue circles) and NRG1tg-type-I mice
(red circles), and their mean 	 SEM (n  10 and 10 cells). p value indicates highly significant difference (t test).
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tions were incubated overnight with Alexa Fluor 488–
conjugated and Alexa Fluor 647–conjugated secondary
antibodies both raised in donkey, respectively, in TBS-Tx
with 1% NHS. Sections containing mid-ventral hippocam-
pus from both hemispheres were scanned using an epiflu-
orescence microscope (AxioImager M2; Zeiss) equipped
with Stereoinvestigator software (MBF Bioscience). Opti-
cal sections of 1 m were acquired using a 20 objective
at a final depth of 20 m from the section surface, while
the first 1 m from the section surface was defined as a
guard zone and not scanned (Bocchio et al., 2015).
Brightness and contrast acquiring settings were adjusted
for each section, to achieve good visualization of all pos-
itive cells for a specific neuromarker across all section
areas. Cell counting was performed offline. Distinct hip-
pocampal regions were visually delineated and analyzed
as individual anatomically defined subregions as follows:
CA1–2 alveus (alv)/stratum oriens (s.o)/stratum pyrami-
dale (s.p), CA1–2 stratum radiatum (s.r)/stratum
lacunosum-moleculare (s.l-m), CA3 alv/s.o/s.p, and CA3
stratum lucidum (s.l)/s.r/s.l-m. Cells were counted when
the cell somata or nuclei came into focus with the optical
dissector.
Immunoblotting
Tissue sample homogenates were prepared from
mouse hippocampus in ice-cold lysis buffer containing 20
mM Tris (pH 7.5), 50 mM NaCl, 1 mM EDTA, 0.1% SDS, 1%
Triton X-100, 2% protease inhibitors (Roche), 1% phos-
phatase inhibitors Cocktail 2 and 3 (Sigma), using a plas-
tic homogenizer, repeated passages through a syringe,
followed by 5-min sonication and 75-min rotation at 4°C.
Next, the homogenates were centrifuged at 4000 g, and
the supernatant was collected. Lysates were quantified
for their total protein content with standard Bradford as-
say (Bio-Rad), diluted to sample buffer containing 100 mM
(or 2 increased) DTT, 10% glycerol, 2% SDS, 2 mM Tris
Figure 4. Quantal current analysis in parvalbumin basket cells
shows unaltered AMPAR mEPSCs in the NRG1tg-type-I mice.
A, Recording of miniature AMPAR- and NMDAR-mediated EP-
SCs (mEPSCs) in identified CA3 area PVBCs (in the presence of
TTX 1 M and PiTX 100 M). A1, Illustration of a recorded and
partially reconstructed PVBC (70-m-thick section) in WT
mouse. Scale, 100 m. A2, AMPAR mEPSCs in a PVBC in the
WT mouse (at –65 mV). Left, the mEPSCs shown in 45-s time
Figure 4. continued
window. Right, six events superimposed in 15-ms time window.
A3, AMPAR mEPSCs in a PVBC in the NRG1tg-type-I mouse. A4,
NMDAR mEPSCs in the same WT mouse PVBC as in A2 after
blockade of AMPARs by NBQX (25 M, recorded at 40 mV). Left,
the mEPSCs shown in 45-s time window. Middle, the mEPSCs
blockade with DL-AP5 (100 M, application indicated by hori-
zontal bar). Right, six superimposed mEPSCs in 80-ms time
window. A5, NMDAR mEPSCs blocked by DL-AP5 in NRG1tg-
type-I mouse PVBC shown in A3. A6, Box plot (median, interquar-
tile range) summarizes AMPAR and NMDAR mEPSC frequency
(measured at least 3 min) in PVBC in WT (blue) and NRG1tg-type-I
(red) mice. A7, Box plot summarizes mEPSC amplitude. Note
moderately but significantly smaller NMDAR mEPSC in the
NRG1tg-type-I mice PVBCs (Mann–Whitney U test). The significant
p value is bolded. B, Unaltered NMDAR- and AMPAR-mediated
mEPSCs in the CA3 area pyramidal cells in NRG1tg-type-I mice.
B1, B2, Sample traces showing AMPAR mEPSCs in pyramidal
cells of both genotypes. B3, B4, Respectively, NMDAR EPSCs in
the same cells. B5, Box plot (median, interquartile range) sum-
marizing the AMPAR- and NMDAR-mediated mEPSC frequency
(WT, blue, NRG1tg-type-I, red). B6, Summary of he AMPAR and
NMDAR mEPSC amplitudes in the two genotypes (Mann–Whit-
ney U test).
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Figure 5. GABAergic synaptic transmission from either PV or CCK cells is not significantly altered in NRG1tg-type-I mice.
A, Experimental design showing optogenetic stimulation (at 473-nm laser spot, 20-m diameter) of GABAergic fibers in the CA3
stratum pyramidale in slices from ChR2-eYFP–transfected mice expressing Cre-protein in either PV cells (A1) or CCK cells (A2).
Left, schematic illustration of the experiment with whole-cell recording in CA3 PCs and optogenetic stimulation focused on stratum
pyramidale (s.p.). Right, confocal microscope images from sample slices (visualized post hoc) showing eYFP fluorescence (green) in
the PV- (above) or CCK-Cre mice. Postsynaptic neurobiotin-filled pyramidal cells are shown red with an inset of a spiny pyramidal cell
apical dendrite. Scale, 50 m. B, Sample experiment showing optogenetically evoked GABAergic IPSCs in a postsynaptic pyramidal
cell using minimal stimulation. Monosynaptic IPSCs (black circles) were evoked by smallest stimulation power eliciting IPSCs in the
PC. Open circles, failures; red circles, additional IPSCs elicited by increased stimulation power. Timing of laser pulses with
representative IPSCs in the experiment is shown above. C, The optogenetically evoked GABAergic IPSCs from PV cell fibers do not
differ significantly between WT mice (blue) and NRG1tg-type-I mice (red; Mann–Whitney U test). C1, A sample trace. Box plots (median,
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HCl, and 0.1% (w/v) bromophenol blue crystals, and in-
cubated at 95°C for 5 min to denature proteins. Protein
lysates were size separated by SDS-PAGE, using 6% or
10% acrylamide gels, and electrophoretically transferred
onto nitrocellulose membranes. After blocking in the Od-
yssey proprietary blocking buffer (LI-COR Biosciences)
for 1 h at room temperature (20–24°C), membranes were
incubated with the primary antibodies overnight at 4°C
(rabbit anti-ErbB4, polyclonal anti-antiserum 5941, 1:900).
Rabbit anti-GADPH (1:10,000) in Odyssey blocking buffer
was supplemented with 0.01% Tween 20. After washes
with PBS Tx (5 times, 5 min), membranes were incubated
with the appropriate fluorescent secondary antibody (goat
anti-rabbit IRDYe 800CW, LI-COR Biosciences) for 1 h at
20–24°C. Finally, after five 5-min washes with PBS Tx, the
membranes were scanned with an infrared scanner (Od-
yssey Clx scanner, LI-COR Biosciences, SCR:014579)
and the digital scans were analyzed with Image Studio
Lite software (LI-COR Biosciences, SCR:014211).
Results
Expression of ErbB4 in the hippocampus of WT and
NRG1 type I–overexpressing mice
Given the well-established role of ErbB4 as the major
receptor to elicit NRG1 signaling cascades in the brain
(Flames et al., 2004; López-Bendito et al., 2006; Kri-
vosheya et al., 2008; Fazzari et al., 2010; Li et al., 2012b),
we visualized the ErbB4 receptor in hippocampal interneu-
rons using rabbit anti-ErbB4 (polyclonal anti-antiserum
5941) immunostaining, which shows high epitope specificity
(Vullhorst et al., 2009). We found that ErbB4 coexpressed
with PV and CCK, the mutually exclusive neuronal mark-
ers (Fig. 1A1,A2 ) that label perisoma-targeting (and also
some dendrite-targeting) hippocampal interneuron types.
Given that NRG1-ErbB4 signaling is known to regulate
interneuron migration, survival, and proliferation during
neurodevelopment (Flames et al., 2004; Li et al., 2012b),
we first investigated whether the NRG1 type I–overex-
pressing mice showed an altered distribution of ErbB4
interneurons in the hippocampus. Fluorescence imaging-
based ErbB4 cell soma counting showed a reduced
density in the NRG1tg-type-I mice compared to the WT
mice in all subfields (Fig.1B1,B2). In the whole hippocam-
pus (including the CA1–CA3 areas) of the WT mice, the
ErbB4 soma density was 4.98  103 cells/mm3 (median,
interquartile range 4.65–5.66  103 cells/mm3), and in the
NRG1tg-type-I mice, 2.82  103 cells/mm3 (median, inter-
quartile range 2.37–3.48  103 cells/mm3; p  0.002,
Mann–Whitney U test; Fig. 1B2). Hippocampal subre-
gions, compared separately, were defined as follows: (1)
stratum pyramidale with infrapyramidal laminae in the
CA1–2 area, (2) suprapyramidal layers in the CA1–2 area,
(3) stratum pyramidale with infrapyramidal laminae in the
CA3 area, (4) suprapyramidal layers in the CA3 area. The
subregion-specific soma counting results are illustrated in
Fig. 1B2 . The cell counts in the CA1 and CA2 areas were
pooled together because of small size of the CA2, and the
result mainly represents the CA1 area.
In contrast, analysis of PV-immunopositive cell somata
showed no difference between the two genotypes, in line
with a previous study using the same NRG1tg-type-I mouse
line (Deakin et al., 2012). Fluorescence imaging-based
PV cell soma counting (Fig. 1C1) in the WTmice revealed
2.44  103 cells/mm3 (median, interquartile range 2.03–
2.74  103 cells/mm3, n  9 sections in 3 mice; Fig. 1C2).
Correspondingly, the PV cell soma density analysis in
the NRG1tg-type-I mice showed 2.28  103 cells/mm3 (me-
dian, interquartile range 2.03–2.63  103 cells/mm3, n 
12 sections in 3 mice; p  0.696, Mann–Whitney U test;
Fig. 1C1,C2). The detected PV cell densities were also
unaltered in the analyzed hippocampal subregions (Fig.
1C2). When we quantified percentages of the ErbB4- and
PV-coexpressing neurons in the two genotypes, we found
that in both genotypes most hippocampal PV cells co-
expressed the ErbB4 receptor (Fig. 1D1). Comparing the
coexpression results in the entire hippocampus did not
show a difference between the genotypes (Fig. 1D2). In
WT mice, the coexpression covered 77.66% (median,
interquartile range 75.85%–86.85%, n  9 slices from 3
mice) of the PV neurons; in the NRG1tg-type-I mice, it
comprised 75.64% (median, interquartile range 72.41%–
80.01%, n  12 slices from 3 mice) of the PV cells (p 
0.166, Mann–Whitney U test), in agreement with previous
studies (Yau et al., 2003; Fazzari et al., 2010; Bean et al.,
2014; see also Neddens and Buonanno, 2010). However,
when comparing the expression in the hippocampal subar-
eas (Fig. 1D2), a significant but small decrease was ob-
served in the coexpression level, specifically in the CA1–2
area (including alveus, stratum oriens, and stratum pyra-
midale) in the NRG1tg-type-I mice (p  0.043, Mann–Whit-
ney U test; Fig. 1D2).
These results show that NRG1 type I overexpression
does not produce significant changes in the coexpression
of ErbB4 and PV in most hippocampal areas or in the
spatial distribution of PV neurons in the hippocampus.
Yet, these data suggest that NRG1 overexpression leads
to altered ErbB4 cell soma count of interneurons other
than those expressing PV. This could either emerge from
changes in the migration, survival, and proliferation of
these cells during neurodevelopment (Flames et al., 2004;
Li et al., 2012a) or be caused by alterations in the expres-
sion and trafficking of the receptor (Longart et al., 2007;
see Discussion).
We found no significant difference in ErbB4 protein
levels between the two genotypes using Western blot
analysis of whole-hippocampus extracts (n  6 including
3 males and 3 females in both genotypes, p  0.310,
Mann–Whitney U test; Fig. 1E1–E3). This discrepancy
continued
interquartile range) show data from all the PCs studied. C2, The evoked IPSC amplitudes. C3, The IPSC half decay. C4, The IPSC
rise time. C5, The IPSC paired-pulse (50 ms) ratio (2nd/1st IPSC amplitude). p values with Mann-Whitney test. D, The IPSCs from
CCK-fibers do not show significant difference between the genotypes. D1, Sample trace. D2–D5, The IPSC amplitude, IPSC half
decay, rise time, and paired-pulse ratio, respectively (Mann–Whitney test).
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may be attributed partly to the fact that the cell density
analysis focused on cells in specific hippocampal subre-
gions, whereas the lysates in the immunoblots comprised
the entire hippocampus, possibly masking subregion-
specific differences (see Discussion).
In conclusion, the above results suggest that expres-
sion level or pattern of the ErbB4 in some hippocampal
CA1 and CA3 cells is altered in response to NRG1 type I
genomic overexpression (see Discussion). In addition, the
analyses confirm earlier findings that ErbB4 is present in
the hippocampal interneurons expressing PV or CCK
(Vullhorst et al., 2009), and that both PV and the PV–
interneuron subpopulations expressing the receptor
ErbB4 are present in the NRG1tg-type-I mouse hippocam-
pus (see Fig. 1B2).
Hippocampal interneurons expressing PV or CCK
have reduced synaptic NMDAR-mediated currents in
the mice overexpressing NRG1 type I
Next, we studied synaptic AMPAR- and NMDAR-
mediated glutamatergic EPSCs in three neuron subpopu-
lations in the CA3 area of acute hippocampal slices; PV
interneurons (Fig. 2A1), CCK interneurons (Fig. 2A2),
which both commonly express the ErbB4 (see Fig. 1), and
pyramidal cells in which the receptor is absent (Vullhorst
et al., 2009). All cells were studied in the whole-cell voltage
clamp mode in hippocampal slices from mice expressing
fluorescent marker (tdTomato) in PV-interneurons (see Ma-
terials and methods). The CCK GABAergic interneurons
were identified post hoc by positive immunoreaction for
cytoplasmic pro-CCK (tested when cell soma was recov-
ered, n  3 in WT control and n  4 in NRG1tg-type-I) or
axonal CB1R (tested when only interneuron axon was
recovered, n 7 and n 7 respectively; Fig. 2A2; Katona
et al., 1999). We applied electrical microelectrode stimu-
lation in the CA3 stratum oriens aiming to activate pre-
dominantly associative-commissural fibers. Blockers for
GABAA and GABAB receptors (picrotoxin, 100 M, and
CGP55845, 1 M) were present in all experiments. We
found that the NMDAR-mediated EPSCs in PV interneu-
rons of the NRG1tg-type-I mice were smaller, in comparison
to the AMPAR EPSCs, than in their WT littermate controls
(measuring a ratio of the NMDAR-EPSC and the AMPAR-
EPSC amplitude, N/A ratio; Fig. 2B1). The evoked average
glutamatergic EPSCs in the NRG1tg-type-I mice were
(median, interquartile range): NMDA EPSC, 19.8 pA,
10.4–45.5 pA; AMPAR EPSC, 110.7 pA, 79.1–136.0 pA.
Correspondingly, the N/A ratio in the NRG1tg-type-I mice
was 0.18, 0.08–0.29 (n  29). In the WT control mice, the
NMDA EPSC amplitude was 47.6 pA (median, interquar-
tile range 29.1–60.8 pA), and the AMPAR EPSC amplitude
127.8 pA, 79.6–214.7 pA. Hence the N/A ratio in WT was
0.28, 0.19–0.42 (n 38). The N/A ratios in PV cells of the
two genotypes were different (p  0.010, Mann–Whitney
U test). Fig. 2B2 shows cumulative histograms of the N/A
ratios measured in the PV interneurons of the two geno-
types.
Likewise, we found that the CCK CA3 area interneu-
rons in the NRG1tg-type-I mice showed smaller N/A ampli-
tude ratio (median 0.57, interquartile range 0.46–0.98,
n  12) than their littermate controls (median 1.12, inter-
quartile range 0.82–1.25, n  10; p  0.019, Mann–
Whitney U test; Fig. 2C1). The EPSC amplitudes in the
CCK interneurons in the NRG1tg-type-I mice were (me-
dian, interquartile range): NMDAR EPSC, 31.8 pA, 26.4–
43.8 pA; AMPAR EPSC, 54.9 pA, 30.8–65.9 pA (n  12).
In the WT CCK cells, the NMDAR EPSC was 52.6 pA
(median, interquartile range 37.1–73.6 pA) and the
AMPAR EPSC was 42.5 pA (median, interquartile range
33.2–58.4 pA; n  10). Sample EPSCs in the CCK
interneurons are illustrated in Fig. 2C1 , and the cumula-
tive histograms of the N/A ratios are shown in Fig. 2C2. In
line with previous observations, CCK interneurons had
larger NMDAR-mediated synaptic currents (compared as
the N/A ratio in the WT mice) than PV cells (p  0.001,
Mann–Whitney U test; Maccaferri and Dingledine, 2002;
Matta et al., 2013).
In contrast to the interneurons, there was no difference
in the N/A ratio across pyramidal cells (PCs) between
genotypes (Fig. 2D1,D2; p  0.761, Mann–Whitney U
test). EPSCs in the NRG1tg-type-I mice PCs were (median,
interquartile range): NMDAR EPSC, 47.5 pA, 34.0–76.2
pA, and AMPAR EPSC, 63.8 pA, 41.9–105.1 pA. Conse-
quently, the N/A ratio in the NRG1tg-type-I mice was 0.80,
0.49–1.11 (n  21). Correspondingly, in the WT mice, the
NMDA EPSC amplitude was 73.3 pA (median, interquar-
tile range 45.0–96.5 pA), and AMPAR EPSC amplitude,
100.1 pA (median, interquartile range 49.1–120.2 pA). The
N/A ratio in the WT PCs was 0.79, 0.63–0.98 (n  22).
Because both interneuron populations comprise vari-
ous specialized cell types (Klausberger and Somogyi,
2008; Pelkey et al., 2017), and glutamatergic synapse
features may vary between individual interneuron types
(Papp et al., 2013), we visualized and anatomically exam-
ined the recorded interneurons (filled with neurobiotin) to
identify basket cells (PVBCs; Fig. 3A) in the PV subpop-
ulation (see Fig. 2B). We confirmed 22 PVBCs (12 in the
WT mice and 10 in the NRG1tg-type-I mice). Interestingly,
the PVBC group in both genotypes showed parametric
distribution of the N/A values (in the NRG1tg-type-I mice
W  0.91, p  0.270; in the WT mice, W  0.96, p 
0.780; Shapiro–Wilk test) showing that the N/A values
have less variation in an identified PV cell type subpop-
ulation than in the entire PV cell population in general.
The PVBC data showed smaller N/A EPSC ratio in the
NRG1tg-type-I mice (0.14 	 0.04, n  10) than in the WT
control mice (0.31 	 0.04, n  12; p  0.006, mean 	
SEM, t test; Fig. 3B1,B2). In addition to the basket cells,
we identified two axo-axonic cells (Nissen et al., 2010) in
the NRG1tg-type-I mice (their average N/A ratios 0.09 and
0.21) and one in the WT control littermates (N/A ratio 
0.18). Because of their low number, these cells were not
separately compared between the genotypes (but the
cells were included in the PV cell pool in Fig. 2).
Quantal current analysis in parvalbumin basket cells
shows unaltered AMPAR-mediated transmission in
NRG1tg-type-I Mice
Because the decreased N/A ratio alone is unable to
distinguish between suppressed NMDAR currents and
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increased AMPAR EPSCs, and because altered NRG1
levels can affect AMPAR-mediated transmission (Abe
et al., 2011), we next studied glutamatergic miniature
currents (mEPSCs) in a new set of identified PVBCs re-
corded in the CA3 area (Fig. 4A1). The cells were voltage
clamped at –65 mV for the AMPAR EPSCs and 40 mV for
the NMDAR EPSCs in presence of tetrodotoxin (TTX, 1
M) and the GABA receptor blockers (picrotoxin, 100 M,
and CGP55845, 1 M). In WT mice PVBCs, the AMPAR-
mediated mEPSCs (Fig. 4A2) occurred at 3.53 Hz (me-
dian, interquartile range 2.32–5.67 Hz, n  7) and had
amplitudes of 28.9 pA (median, interquartile range 25.3–
32.6 pA, n  7). Correspondingly, in the NRG1tg-type-I
mice, the AMPAR mEPSC (Fig. 4A3) frequency was 3.28
Hz (median, interquartile range 2.51–3.92 Hz, n  6) and
the amplitude 28.3 pA (median, interquartile range 24.8–
34.7 pA, n  6). Neither the AMPAR mEPSC frequency
(p  0.954) nor the amplitude (p  1.00) differed between
genotypes in the PVBCs (Mann–Whitney U test).
In addition, we measured the NMDAR-mediated mEP-
SCs in the same identified PVBCs following wash-in of
NBQX (25 M). One recording was lost before the NBQX
application and therefore the n number is smaller than
above. We found that the frequency of detected NMDAR
mEPSCs was not different between WT PVBCs (Fig. 4A4;
4.27 Hz, 1.48–6.60 Hz, n  6) and the NRG1tg-type-I
PVBCs (Fig. 4A5; 2.90 Hz, 2.34–4.33 Hz, n  6; median
and interquartile range, p  0.589, Mann–Whitney U test;
Fig. 4A6). Yet, the amplitude of the NMDAR mEPSCs in
NRG1tg-type-I mice (19.0 pA, 17.6–20.1 pA; median, inter-
quartile range) was moderately but significantly lower than
in WT littermates (21.8 pA, 20.8–30.0 pA; p  0.026,
Mann–Whitney U test). These results are summarized in
Fig. 4A6,A7.
We also recorded mEPSCs in the CA3 area PCs and
found that neither AMPAR- nor NMDAR-mediated mEP-
SCs differed between the genotypes. In the WT PCs, the
AMPAR mEPSC (Fig. 4B1) values were 1.15 Hz (median,
interquartile range 1.10–1.70 Hz, n  7) and 20.8 pA
(median, interquartile range 18.8–21.9 pA, n  7). Corre-
spondingly, in the NRG1tg-type-I mice (Fig. 4B2), the values
were 0.79 Hz (median, interquartile range 0.54–1.25 Hz, n
 10, p  0.223 vs. the WT PCs) and 21.6 pA (median,
interquartile range 19.0–25.0 pA, n  10, p  0.354 vs.
the WT PCs; Mann–Whitney U test). Respectively, the
NMDAR mEPSCs in the WT PCs (Fig. 4B3) occurred at
2.54 Hz (median, interquartile range 1.60–3.71 Hz, n  5)
with amplitude of 18.5 pA (median, interquartile range
17.8–24.1 pA, n  5). The NMDAR mEPSCs in the
NRG1tg-type-I PCs (Fig. 4B4) occurred at 1.94 Hz (median,
interquartile range 1.71–2.87 Hz, n  9, p  0.689 vs. the
WT PCs) showing an amplitude of 19.3 pA (median, inter-
quartile range 18.5–20.6 pA, n  9, p  0.790 vs. the WT
PCs). The results are summarized in Fig. 4B5,B6.
The findings of unchanged AMPAR mEPSCs in the
PVBCs and PCs (and the moderate reduction of the
NMDAR mEPSC amplitude specifically in the PVBCs in
the NRG1tg-type-I mice) indicate that the altered N/A ratio
observed (Fig. 3) was caused by reduced postsynaptic
NMDAR currents in the NRG1tg-type-I mice PVBCs.
GABAergic inhibitory currents from parvalbumin- or
cholecystokinin-expressing CA3 interneurons are not
altered in NRG1tg-type-I mice
Given that alterations in NRG1 levels can acutely
change inhibitory synapses and modify them long term
(Okada and Corfas, 2004; Woo et al., 2007; Chen et al.,
2010; Yin et al., 2013; Agarwal et al., 2014), we studied
whether GABAergic synaptic output from interneurons
expressing either PV or CCK is also altered in the NRG1tg-
type-I mice. To selectively stimulate axons from these in-
terneurons, we prepared slices from NRG1tg-type-I and WT
mice expressing Cre-protein either in PV cells or CCK
interneurons and transduced with a Cre-dependent adeno-
associated virus (AAV)-channelrhodopsin-2 (ChR2)-eYFP
construct (see Materials and methods). Expression of the
construct in the two types of GABAergic fibers is illustrated
in Fig. 5A1,A2. GABAergic IPSCs were elicited in the CA3
area pyramidal cells stimulating the interneuron axons
locally with brief laser light pulses (3 ms, 473 nm) focused
in stratum pyramidale. Stimulation intensity was set to use
minimal laser power required for stable IPSCs (Fig. 5B). In
all experiments, the postsynaptic pyramidal cells (voltage
clamped at 0 to 10 mV) were recorded in the presence of
glutamate receptor blockers NBQX (25 M) and DL-AP5
(100 M). The optically evoked IPSCs were blocked with
picrotoxin (100 M) in all experiments tested (n  8 of 8 in
IPSCs from PV fibers, and n  3 of 3 from CCK fibers).
We found that the IPSCs did not differ significantly
between the genotypes for either PV or CCK GABAe-
rgic synapses (Mann–Whitney U test). For PV fibers, the
evoked IPSC amplitudes (Fig. 5C1) were 43.6 pA, 34.3–
82.0 pA (median, interquartile range; n  18 cells) in WT
mice, and 44.8 pA, 36.2–82.7 pA in NRG1tg-type-I mice
(n 16 cell, p 0.74 vs. WT; Fig. 5C2). The IPSC rise time
(from 20% to 80% of the peak) values in the WT were 0.88
ms, 0.76–1.20 ms (n  18 cells), and in the NRG1tg-type-I
mice 0.97 ms, 0.87–1.49 ms (n  16, p  0.208 vs. WT;
Fig. 5C3). The IPSCs from the WT mice PV fibers
showed a decay half-time of 9.4 ms, 8.6–12.4 ms (n 
18), and the decay half times in the NRG1tg-type-I PV cells
were 10.1 ms, 9.0–12.8 ms (n  16, p  0.32 vs. WT; Fig.
5C4). The paired-pulse ratio (PPR, 50-ms interval, 2nd
IPSC/1st IPSC amplitude) in the WT mice was 0.69, 0.60–
0.79 (n  18), and in the NRG1tg-type-I 0.58, 0.80–0.76
(n  16, p  0.173 vs. WT; Fig. 5C5).
The IPSC amplitudes evoked from the CCK fibers (Fig.
5D1) were 38.0 pA, 23.9–45.4 pA in WT mice (n  5), and
23.4 pA, 18.0–44.7 pA in NRG1tg-type-I mice (n  6, p 
0.662 vs. WT; Fig. 5D2). The IPSC rise time (from 20% to
80% of the peak) in the WT mice was 2.40 ms, 1.40–3.60
ms (n  5 cells), and 3.30 ms, 1.29–4.30 ms in the
NRG1tg-type-I mice (n  5, p  0.94 vs. WT; Fig. 5D3). The
decay half time in the WT was 7.7 ms, 6.3–12.2 ms (n 5),
and in the NRG1tg-type-I mice it was 7.4 ms, 3.4–12.3 ms
(n 6, p 0.79 vs. WT; Fig. 5D4). The IPSCs evoked from
the CCK fibers showed PPR of 0.61, 0.32–0.66 in WT
(n  5), and 0.75, 0.54–1.22 in the NRG1tg-type-I mice (n 
6, p  0.33 vs. WT; Fig. 5D5).
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Reduced NMDAR-driven recurrent inhibition in the
hippocampus in NRG1tg-type-I mice
Finally, we investigated whether the reduced synaptic
NMDAR-mediated transmission in these two common
recurrent inhibition interneuron subpopulations had con-
sequences for the GABAergic inhibition evoked by repet-
itive firing of the hippocampal glutamatergic neurons. To
study this, we optogenetically stimulated glutamatergic
fibers, focusing the laser light pulses in stratum pyrami-
dale and stratum oriens, aiming to activate the recurrent
disynaptic GABAergic pathway. We did the experiments
in the CA1 area to avoid polysynaptic glutamatergic
discharge generated in the CA3 recurrent glutamatergic
circuits (Maccaferri and McBain, 1995). We used hip-
pocampal slices of the NRG1tg-type-I / mice and their
littermate WT controls both crossed with CaMKII-Cre	
and transduced with the AAV-ChR2-eYFP construct in the
hippocampus (Fig. 6A). We made a translaminar surgical
cut in the slices from alveus to stratum lacunosum-moleculare
in the CA1-CA2 area border to exclude the CA3 area
recurrent excitatory loop and polysynaptic discharges
(Maccaferri and McBain, 1995).
We applied bursts of five pulses of stimuli at 20 Hz
every 60 s to generate disynaptic IPSCs in the CA1 area
pyramidal cells. The IPSCs were recorded at a reversal
potential of the EPSCs (11.1 	 0.7 mV, mean 	 SEM)
elicited in the same cells (n  13 comprising 7 cells in the
NRG1tg-type-I mice and 6 cells in the WT controls; Fig.
6B1,B2). Long-term plasticity blockers KN-62 (3 M) and
MCPG (200 M) were present in all experiments for long-
term stability of the disynaptic IPSCs (Perez et al., 2001;
Kullmann and Lamsa, 2011; Campanac et al., 2013). After
a stable baseline (at least 5 min), NMDAR blocker DL-AP5
(100 M) was washed in (Fig. 6C1,C2). This suppressed
the evoked recurrent GABAergic IPSC in the WT mice to
0.66 of baseline (charge median, interquartile range 0.61–
0.71, p  0.031 vs. baseline, n  6 cells), and in the
NRG1tg-type-I mice to 0.74 (charge median, interquartile
range 0.66–0.83, p  0.026 vs. baseline, n  7 cells)
compared to the baseline (Mann–Whitney rank sum test).
The IPSC charge was compared in each experiment be-
tween the last 3 min in baseline, and in an equal time
window in the presence of DL-AP5 (at 5–8 min after
DL-AP5 application). The suppression of the disynaptic
Figure 6. Reduced NMDAR-driven recurrent hippocampal inhibition in NRG1tg-type-I mice. A, Schematic summarizes the experimental
design. Optogenetic stimulation of CA1 area pyramidal cell fibers expressing ChR2 (green, CAMKII-Cre mice transfected with
AAV2-ChR2-eYFP). Recurrent inhibitory IPSCs are generated by laser spot (473-nm, 3-ms) stimulation focused in stratum pyramidale
(s.p.) and oriens (s.o.). B, Sample experiments showing averaged (5) recurrent IPSCs in the CA1 pyramidal cells, evoked by the
optogenetic stimulation (5 pulses at 20 Hz) in WT (B1) and NRG1tg-type-I (B2) mice. Black traces show IPSCs in baseline; green is in
the presence of NMDAR blocker DL-AP5 (100 M, at 5–8 min after DL-AP5 application). The IPSCs were recorded at the reversal
potential of EPSCs. The IPSCs were fully blocked with NBQX (25 M, gray traces). C, Plots show the recurrent IPSC charge in sample
experiments in the WT (C1) and NRG1tg-type-I (C2) mouse. Wash-in of DL-AP5 and NBQX is indicated by green and gray horizontal
bars, respectively. D, The hippocampal recurrent IPSCs in the NRG1tg-type-I mice show reduced sensitivity to the NMDAR antagonist.
Box plot (median, interquartile range) summarizes the effect of DL-AP5 (100 M) on the recurrent IPSC charge in WT (blue) and
NRG1tg-type-I (red) mice. The IPSC charge in the presence of DL-AP5 (and in the presence of NBQX) is normalized with the baseline
for each experiment. p value with Mann–Whitney U test.
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IPSCs by the NMDAR blocker was larger in the WT than in
the NRG1 mice (p  0.014, Mann–Whitney U test). The
IPSCs were fully blocked at the end by NBQX (25 M) in all
experiments tested to verify their disynaptic origin (n  4
in the WT controls, and n  4 in the NRG1tg-type-I mice).
The results, summarized in Fig. 6D, indicate smaller
NMDAR-mediated excitatory drive of hippocampal GABAe-
rgic interneurons in the NRG1tg-type-I mice compared to their
WT littermates.
Discussion
Our results show that transgenic overexpression of
NRG1 type I, an isoform of NRG1 that has elevated levels
in some patients with SZ (Hashimoto et al., 2004; Law
et al., 2006; Chong et al., 2008; Weickert et al., 2012; see
also Boer et al., 2009; Parlapani et al., 2010; Hahn, 2011),
is associated with a hypofunction of NMDAR-mediated syn-
aptic signaling in two major GABAergic interneuron popula-
tions in mouse hippocampus.
The reduced ratio of NMDAR- to AMPAR-mediated syn-
aptic currents was observed in the hippocampal GABAergic
interneuron populations expressing either PV or CCK, but
not in PCs. This finding on cell type specificity is in line
with the cortical ErbB4 expression pattern: various stud-
ies have demonstrated that ErbB4 expression is predom-
inant in GABAergic interneurons, whereas it is absent in
PCs (Vullhorst et al., 2009; Fazzari et al., 2010; Neddens
and Buonanno, 2010; Abe et al., 2011; Pitcher et al., 2011;
Del Pino et al., 2017). As illustrated in Fig. 1, we confirmed
here the ErbB4 expression in both PV and CCK in-
terneurons, as has been previously reported (Vullhorst
et al., 2009). It should be noted that because of contrast
adjustment, Fig. 1A2 shows low CCK-Cre–dependent
fluorophore intensity in the CA3 pyramidal cells compared
to interneurons, although CCK is expressed in both cell
populations (Burgunder and Young, 1990; Geibel et al.,
2014; Rombo et al., 2015).
ErbB4 interneurons expressing either PV or CCK were
found in the NRG1tg-type-I mice, but the cell soma counting
analysis indicated that the density of ErbB4 neurons not
coexpressing PV is reduced in the hippocampus of NRG1
type I–overexpressing mice. This suggests that in some
interneurons, either the ErbB4 receptor abundance has
changed or detectable ErbB4 immunoreactivity has de-
creased (e.g. due to an altered subcellular localization or
a change in epitope accessibility). Surprisingly, Western
blot did not detect the reduction of ErbB4 expression,
although the detectable ErbB4 neuron soma number
was reduced. We offer two possible explanations for this.
The counting of immunohistochemically revealed ErbB4
cell somata is a nonquantitative method (giving cells clearly
ErbB4 or cells not confirmed positive). If the antibody-
labeled fluorescence signal in the soma is low, it becomes
increasingly challenging to confirm it as immunopositive
compared to background. This could happen in the NRG1
type I–overexpressing mice without a significant change
in total hippocampal ErbB4 protein level, if subcellular
location of the ErbB4 changed (decreased in soma) or the
ErbB4 protein is internalized in some interneurons (Liu
et al., 2007, Longart et al., 2007), making its detection by
the antibody less evident. The discrepancy may also be
attributed to the fact that the cell density analysis focused
on cells in specific hippocampal subregions, whereas the
lysates in the immunoblots comprised the entire hippocam-
pus, possibly masking subregion-specific differences.
We found that synaptic NMDAR currents were reduced
in interneurons expressing PV or CCK, but not in pyrami-
dal cells in the NRG1tg-type-I mice. Furthermore, we show
that not only is the NMDAR-mediated synaptic compo-
nent reduced in comparison to the AMPAR currents in the
CCK cells or PV cells, but a similar significant change is
also seen in anatomically identified PV basket cells. The
analyses of the quantal miniature currents in identified
PV basket cells indicate that the reduced NMDAR- to
AMPAR-mediated synaptic responses are due to smaller
postsynaptic NMDAR currents, rather than increased AMPAR
EPSCs. Finally, we show reduced NMDAR-dependent ex-
citatory drive of recurrent GABAergic inhibition in the hip-
pocampus of the NRG1 type I–overexpressing mice using
optogenetically driven selective stimulation of hippocampal
pyramidal cells.
Of note, in this transgenic mouse line, the overexpres-
sion of NRG1 type I is under the Thy-1.2 promoter, which
is not equally expressed in all hippocampal pyramidal
cells (Dobbins et al., 2018). This raises a possibility that
NRG1 release in the hippocampus is not homogeneous,
having variable effects on ErbB4-positive cells. This might
at least partially explain the N/A ratio variation in PV cells
of the NRG1-overexpressing mice illustrated in Fig. 2.
However, the N/A ratio variation may also emerge from
lack of the NRG1 receptor in some PV cells and CCK
interneurons (Bean et al., 2014).
The results suggest that NMDAR-signaling abnormali-
ties in these two major GABAergic interneuron popula-
tions may contribute to the hippocampal pathophysiology
thought to occur in SZ (Harrison et al., 2003; Gonzalez-
Burgos et al., 2011; Curley and Lewis, 2012). In this respect,
our results bring together three theories of SZ pathophysi-
ology; genetic heritability, inhibitory circuit dysfunction, and
NMDAR hypofunction affecting GABAergic inhibitory in-
terneurons such as PV basket cells (Zylberman et al.,
1995; Lisman et al., 2008; Belforte et al., 2010; Korotkova
et al., 2010; Lewis et al., 2011; Gonzalez-Burgos and
Lewis, 2012; Volk and Lewis, 2014; Banerjee et al., 2015;
Krystal, 2015). Malfunction of PV basket cells has been
commonly suggested to underlie aberrant coordinated
network activities, in particular the gamma frequency os-
cillations, is associated with cognitive dysfunction in ani-
mal models (Cho et al., 2015), and is hypothesized to do
so as well in SZ patients (Buonanno, 2010; Uhlhaas and
Singer, 2010; Gonzalez-Burgos and Lewis, 2012; Harrison
et al., 2012; Marín, 2012; Nakazawa et al., 2012). Inter-
estingly, the specific alterations of gamma oscillation
features that were observed in hippocampal slice prepa-
rations from the NRG1tg-type-I mice (Deakin et al., 2012)
differed from findings of in vivo studies in which NMDARs
were selectively knocked out in PV-expressing interneu-
rons (Korotkova et al., 2010; Carlén et al., 2012). In fact, it
has been proposed that NMDAR hypofunction in PV
cells renders the brain networks more prone to exhibit the
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schizophrenia-associated behavioral and electrophysio-
logical alterations, and that the actual phenotypes de-
velop when NMDAR hypofunction simultaneously
coexists in other neuron types (Bygrave et al., 2016).
Importantly, our results here show postsynaptic suppres-
sion of the NMDAR signaling in interneurons expressing
CCK. In physiologic conditions, these hippocampal in-
terneurons have large synaptic NMDAR-mediated cur-
rents (Fricker and Miles, 2000; Maccaferri and Dingledine,
2002; Matta et al., 2013). Thus, it is likely that the altera-
tions observed in the NRG1tg-type-I mouse hippocampal
network activity and hippocampus-dependent behavior
(Deakin et al., 2009, 2012) emerge at least partially from
NMDAR hypofunction in the PV and CCK interneuron
subpopulations. Although we failed to detect changes in
AMPAR-mediated glutamatergic currents or the function
of GABAergic synapses, it is possible that these can be
subject to changes at a later stage of the phenotype
progression also in the NRG1 type I mutant mice (Woo
et al., 2007; Fazzari et al., 2010; Wen et al., 2010; Abe
et al., 2011; Ting et al., 2011).
In summary, our results indicate that synaptic NMDAR-
mediated signaling in hippocampal interneurons is sensi-
tive to chronically elevated NRG1 type I levels. Further
studies will be required to determine the mechanism by
which NRG1 type I overexpression results in the observed
NMDAR hypofunction, and to what extent these altera-
tions are sufficient to explain the previously reported phe-
notypes in these mice (Michailov et al., 2004; Deakin et al.,
2009, 2012). Possible cellular mechanisms underlying the
NMDAR hypofunction include altered receptor subunit
phosphorylation (Hahn et al., 2006; Bjarnadottir et al.,
2007; Pitcher et al., 2011; Banerjee et al., 2015) or mod-
ulation of the trafficking and expression of NMDAR sub-
units (Ozaki et al., 1997; Gu et al., 2005; Abe et al., 2011;
Luo et al., 2014). Importantly, it has been shown that
neuregulin 2 (NRG2), which also signals via ErbB4, facil-
itates the physical interaction of ErbB4 with the NMDAR
GluN2B subunit, leading to internalization of the subunit
and hence NMDAR hypofunction (Vullhorst et al., 2015).
Finally, the changes in NMDAR-mediated synaptic trans-
mission observed in transgenic NRG1 type I mice could in
part mirror what takes place in SZ, given the elevated
NRG1 type I expression seen in the brain in the disease.
Further studies are needed to explore this possibility and
the potential role of therapeutic interventions targeting the
NRG1 signaling pathway.
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